{
    "2021-12-15": [
        [
            {
                "time": "",
                "original_text": "腰部位药企IPO也难了，沃森生物终止港股挂牌，但20亿的研发费用缺口怎么办？",
                "features": {
                    "keywords": [
                        "药企",
                        "IPO",
                        "沃森生物",
                        "港股",
                        "研发费用",
                        "缺口"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}